| Literature DB >> 35822036 |
Abstract
Entities:
Keywords: animal model of aging; biomarker of aging; healthspan; lifespan; theory of aging
Year: 2021 PMID: 35822036 PMCID: PMC9261341 DOI: 10.3389/fragi.2021.676573
Source DB: PubMed Journal: Front Aging ISSN: 2673-6217
Animal model's strengths and limitations in aging research.
|
|
|
|
|---|---|---|
|
| Short lifespan. Fast evaluation of interventions. Low costs. | Invertebrate model. Low translationality to humans. |
|
| Short lifespan. Fast evaluation of interventions. Low costs. | Invertebrate model. Low translationality to humans. |
|
| Short lifespan. Fast evaluation of interventions. Low costs. | Invertebrate model. Low translationality to humans. |
|
| Appropriate for evaluation of interventions | Organs are quite different from those in humans. |
| Senescence prone inbred strains | Appropriate for evaluation of interventions | Significant differences at a pharmacokinetic level. Lifespan extension could vary between rodent's genders. |
| Genetically heterogeneous (HET) mouse model | Developed by the National Institute on Aging interventions testing program as the most adequate mammal mice model in aging | Significant differences at a pharmacokinetic level. Lifespan extension could vary between rodent's genders. |
| Rodent models of progeria | Reduction in time, labor and costs for lifespan studies, as well as the ability to target accelerated aging to specific organs. | Effects of premature aging, not aging itself. Significant differences at a pharmacokinetic level. |
| Non-human primate models of aging | Best extrapolation of the results to our species. | Expensive. Long time to obtain results. |